ZEPP vs GRMN

For growth investors, Garmin Ltd.

(GRMN) is the stronger pick with 15. 1% revenue growth year-over-year, versus -46. 6% for Zepp Health Corporation (ZEPP). Garmin Ltd. (GRMN) offers the better valuation at 27. 9x trailing P/E (25. 1x forward), making it the more compelling value choice. Analysts rate Garmin Ltd. (GRMN) a "Hold" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Garmin Ltd.

is actually cheaper at 25. 1x.

Over the past 5 years, Garmin Ltd.

(GRMN) delivered a total return of +79. 2%, compared to -66. 4% for Zepp Health Corporation (ZEPP). Over 10 years, the gap is even starker: GRMN returned +558. 6% versus ZEPP's -72. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Garmin Ltd.

(GRMN) is the lower-risk stock at 1. 29β versus Zepp Health Corporation's 1. 66β — meaning ZEPP is approximately 29% more volatile than GRMN relative to the S&P 500. On balance sheet safety, Garmin Ltd. (GRMN) carries a lower debt/equity ratio of 2% versus 72% for Zepp Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Garmin Ltd.

(GRMN) is pulling ahead at 15. 1% versus -46. 6% for Zepp Health Corporation (ZEPP). On earnings-per-share growth, the picture is similar: Garmin Ltd. grew EPS 17. 7% year-over-year, compared to -1642. 9% for Zepp Health Corporation. Over a 3-year CAGR, GRMN leads at 14. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Garmin Ltd.

(GRMN) is the more profitable company, earning 23. 0% net margin versus -41. 6% for Zepp Health Corporation — meaning it keeps 23. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRMN leads at 25. 9% versus -25. 9% for ZEPP. At the gross margin level — before operating expenses — GRMN leads at 58. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Garmin Ltd.

(GRMN) trades at 25. 1x forward P/E versus 177. 0x for Zepp Health Corporation — 151. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GRMN: 12. 0% to $269. 00.

In this comparison, GRMN (1.

4% yield) pays a dividend. ZEPP does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Garmin Ltd.

(GRMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 29), 1. 4% yield, +558. 6% 10Y return). Zepp Health Corporation (ZEPP) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GRMN: +558. 6%, ZEPP: -72. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZEPP is a small-cap quality compounder stock; GRMN is a mid-cap high-growth stock. GRMN pays a dividend while ZEPP does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.